Current Drug Targets
Title:Editorial (Thematic Issue: Targeting Defective DNA Damage Response Signaling)
Volume: 17 Issue: 2
Author(s): Loredana Campo and Eun-Kyoung Breuer
Affiliation:
Export Options
About this article
Cite this article as:
Campo Loredana and Breuer Eun-Kyoung, Editorial (Thematic Issue: Targeting Defective DNA Damage Response Signaling), Current Drug Targets 2016; 17 (2) . https://dx.doi.org/10.2174/138945011702160105145550
DOI https://dx.doi.org/10.2174/138945011702160105145550 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
45
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Triterpene Derivatives as Inhibitors of Protein Involved in the Inflammatory Process: Molecules Interfering with Phospholipase A2, Cycloxygenase, and Lipoxygenase
Current Drug Targets Energetics of Quadruplex-Drug Recognition in Anticancer Therapy
Current Cancer Drug Targets Micro/Nanoparticle Design and Fabrication for Pharmaceutical Drug Preparation and Delivery Applications
Current Drug Therapy The Role of Culture and Ethnicity in the Adjustment to Gynecological Cancer
Current Women`s Health Reviews Microfilament Actin Remodeling as a Potential Target for Cancer Drug Development
Current Cancer Drug Targets A Combined Approach with Rituximab Plus Anti-TRAIL-R Agonistic Antibodies for the Treatment of Haematological Malignancies
Current Pharmaceutical Design Targeting Receptor Tyrosine Kinase Pathways in Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry YB-1 Activities in Oncogenesis: Transcription and Translation
Current Cancer Therapy Reviews The Preclinical Bases of the Rational Combination of Paclitaxel and Antiangiogenic Drugs
Clinical Cancer Drugs 5-Aminoisoquinolin-1-one (5-AIQ), a Water-Soluble Inhibitor of the Poly(ADP-Ribose)Polymerases (PARPs)
Current Medicinal Chemistry Recent Advances in the Chemistry and Synthesis of Thienopyrazine, Pyrrolopyrazine and Furopyrazine Derivatives
Current Organic Chemistry A Therapeutic Potential of Animal β-hairpin Antimicrobial Peptides
Current Medicinal Chemistry Estrogen Receptor Expression and its Relevant Signaling Pathway in Prostate Cancer: A Target of Therapy
Current Molecular Pharmacology Recent Advances in Hematopoietic Stem Cell-Mediated Regeneration
Recent Patents on Regenerative Medicine TRAIL-Based Therapeutic Approaches for the Treatment of Pediatric Malignancies
Current Medicinal Chemistry Phage Display Applications for Molecular Imaging
Current Pharmaceutical Biotechnology Modular Protein Engineering in Emerging Cancer Therapies
Current Pharmaceutical Design Deep Penetration of Nanoparticulate Drug Delivery Systems into Tumors: Challenges and Solutions
Current Medicinal Chemistry The Biology of Cholecystokinin and Gastrin Peptides
Current Topics in Medicinal Chemistry Targeting Microtubules to Inhibit Angiogenesis and Disrupt Tumour Vasculature:Implications for Cancer Treatment
Current Cancer Drug Targets